Kenichi Suda

5.8k total citations · 2 hit papers
130 papers, 4.3k citations indexed

About

Kenichi Suda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kenichi Suda has authored 130 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Pulmonary and Respiratory Medicine, 80 papers in Oncology and 45 papers in Molecular Biology. Recurrent topics in Kenichi Suda's work include Lung Cancer Treatments and Mutations (102 papers), Lung Cancer Research Studies (39 papers) and Cancer therapeutics and mechanisms (19 papers). Kenichi Suda is often cited by papers focused on Lung Cancer Treatments and Mutations (102 papers), Lung Cancer Research Studies (39 papers) and Cancer therapeutics and mechanisms (19 papers). Kenichi Suda collaborates with scholars based in Japan, United States and China. Kenichi Suda's co-authors include Tetsuya Mitsudomi, Kenji Tomizawa, Yasushi Yatabe, Fred R. Hirsch, Paul A. Bunn, Jacinta Wiens, Yoshihiko Maehara, Masaki Shimoji, Hiroshi Mizuuchi and Toshiki Takemoto and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kenichi Suda

123 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New and emerging targeted treatments in advanced non-small-cell lung cancer

2016 359 citations Fred R. Hirsch, Kenichi Suda et al. profile →
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenichi Suda Japan	35	2.8k	2.5k	1.7k	890	308	130	4.3k
Andrew M. Rogers United States	12	2.7k 1.0×	2.6k 1.0×	2.4k 1.4×	994 1.1×	568 1.8×	21	4.7k
Misako Nagasaka United States	31	1.8k 0.6×	1.9k 0.8×	1.2k 0.7×	646 0.7×	275 0.9×	205	3.2k
Sarah B. Goldberg United States	33	2.7k 1.0×	3.0k 1.2×	1.3k 0.7×	611 0.7×	231 0.8×	143	4.8k
Ximing Tang United States	32	1.6k 0.6×	1.7k 0.7×	1.9k 1.1×	1.0k 1.2×	256 0.8×	70	3.8k
Santiago Viteri Spain	31	2.1k 0.8×	2.1k 0.8×	1.3k 0.8×	903 1.0×	324 1.1×	169	3.4k
Kenneth S. Thress United States	26	4.0k 1.4×	3.4k 1.3×	2.5k 1.5×	1.9k 2.1×	513 1.7×	48	5.7k
Ryohei Katayama Japan	31	3.2k 1.2×	3.2k 1.3×	2.9k 1.7×	1.0k 1.2×	730 2.4×	86	5.4k
Vanesa Gregorc Italy	33	2.0k 0.7×	2.2k 0.9×	1.1k 0.6×	477 0.5×	162 0.5×	136	3.4k
Diane Prager United States	29	3.5k 1.3×	3.5k 1.4×	1.6k 0.9×	731 0.8×	196 0.6×	56	5.4k
Shigeki Shimizu Japan	29	1.9k 0.7×	1.4k 0.6×	1.0k 0.6×	481 0.5×	262 0.9×	108	3.5k

Countries citing papers authored by Kenichi Suda

Since Specialization

Citations

This map shows the geographic impact of Kenichi Suda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenichi Suda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenichi Suda more than expected).

Fields of papers citing papers by Kenichi Suda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenichi Suda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenichi Suda. The network helps show where Kenichi Suda may publish in the future.

Co-authorship network of co-authors of Kenichi Suda

This figure shows the co-authorship network connecting the top 25 collaborators of Kenichi Suda. A scholar is included among the top collaborators of Kenichi Suda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenichi Suda. Kenichi Suda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suda, Kenichi, Akira Hamada, Toshio Fujino, et al.. (2025). Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study. Cells. 14(17). 1386–1386.

Suda, Kenichi, Akira Hamada, Shuta Ohara, et al.. (2024). Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study. Biomedicines. 12(7). 1412–1412. 6 indexed citations

Ohara, Shuta, Kenichi Suda, Akira Hamada, et al.. (2024). Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer. Thoracic Cancer. 15(31). 2229–2234. 1 indexed citations

Fukuda, Shota, Kenichi Suda, Akira Hamada, & Yasuhiro Tsutani. (2023). Recent Advances in Perioperative Immunotherapies in Lung Cancer. Biomolecules. 13(9). 1377–1377. 8 indexed citations

Hamada, Akira, Kenichi Suda, Masaya Nishino, et al.. (2023). Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. Journal of Thoracic Oncology. 19(1). 71–79. 9 indexed citations

Guo, Kai, Zhiqiang Ma, Yujiao Zhang, et al.. (2022). HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway. Journal of Experimental & Clinical Cancer Research. 41(1). 91–91. 40 indexed citations

Ohara, Shuta, Kenichi Suda, Toshio Fujino, et al.. (2021). Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. Lung Cancer. 154. 84–91. 10 indexed citations

Ohara, Shuta, Kenji Tomizawa, Shigeki Shimizu, et al.. (2019). Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. SHILAP Revista de lepidopterología. 5(1). 105–105.

Suda, Kenichi, Isao Murakami, Hui Yu, et al.. (2018). CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Molecular Cancer Therapeutics. 17(10). 2257–2265. 39 indexed citations

10.

Fujino, Toshio, Kenichi Suda, Yoshihisa Kobayashi, et al.. (2018). P1.13-41 In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping. Journal of Thoracic Oncology. 13(10). S598–S598. 1 indexed citations

11.

Tomizawa, Kenji, Shigeki Shimizu, Shuta Ohara, et al.. (2017). Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer. 112. 57–61. 11 indexed citations

12.

Terashima, Masato, Yosuke Togashi, Katsuaki Sato, et al.. (2016). Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2. Clinical Cancer Research. 22(14). 3663–3671. 15 indexed citations

13.

Yu, Hui, Yayi He, Christopher J. Rivard, et al.. (2016). PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines. Journal of Thoracic Oncology. 11(11). S281–S281. 1 indexed citations

14.

Kobayashi, Yoshihisa, Yosuke Togashi, Yasushi Yatabe, et al.. (2015). EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clinical Cancer Research. 21(23). 5305–5313. 164 indexed citations

15.

Mizuuchi, Hiroshi, Kenichi Suda, Katsuaki Sato, et al.. (2015). Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib. PLoS ONE. 10(4). e0123901–e0123901. 13 indexed citations

16.

Kohno, Mikihiro, Tatsuro Okamoto, Kenichi Suda, et al.. (2014). Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations. Clinical Cancer Research. 20(13). 3613–3622. 32 indexed citations

17.

Suda, Kenichi & Tetsuya Mitsudomi. (2014). Successes and Limitations of Targeted Cancer Therapy in Lung Cancer. Progress in tumor research. 41. 62–77. 34 indexed citations

18.

Nakagawa, Takayuki, Shinji Takeuchi, Tadaaki Yamada, et al.. (2012). Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer. Molecular Cancer Therapeutics. 11(10). 2149–2157. 74 indexed citations

19.

Suda, Kenichi, Kenji Tomizawa, Yasushi Yatabe, & Tetsuya Mitsudomi. (2011). Lung cancers unrelated to smoking: characterized by single oncogene addiction?. International Journal of Clinical Oncology. 16(4). 294–305. 20 indexed citations

20.

Suda, Kenichi, Isao Murakami, Tatsuya Katayama, et al.. (2010). Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer. Clinical Cancer Research. 16(22). 5489–5498. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact